Research on correlation between immunophenotype and c-MYC rearrangement in diffuse large B-cell lymphoma

doi:10.3969/j.issn.1673-8640.2013.04.014

›› 2013, Vol. 28 ›› Issue (4): 308-311.DOI: 10.3969/j.issn.1673-8640.2013.04.014

Previous Articles Next Articles

Research on correlation between immunophenotype and c-MYC rearrangement in diffuse large B-cell lymphoma

1. Department of Hematology， the First People′s Hospital of Changzhou，Jiangsu Changzhou 213003,China; 2. Department of Clinical Laboratory，the First People′s Hospital of Changzhou，Jiangsu Changzhou 213003，China

Received:2012-03-13 Revised:2012-04-19 Online:2013-04-30 Published:2013-04-05

Abstract

Abstract: Objective　To investigate the correlation between immunophenotype and c-MYC rearrangement in diffuse large B-cell lymphoma (DLBCL). Methods　According to the lymphoma cell immune marker CD10，B cell lymphoma 6 (BCL-6) and multiple myeloma oncogene 1 (MUM-1) expression levels，46 cases of DLBCL were classified into germinal center B cell-like(GCB) group and non-germinal center B cell-like(non-GCB) group. c-MYC rearrangement status was analyzed by fluorescence in situ hybridization (FISH) in GCB and non-GCB groups. Results　Of the 46 DLBCL cases，4 cases (8.7%) had c-MYC rearrangement. The 4 cases of c-MYC rearrangement belonged to the GCB group. There was no c-MYC rearrangement in non-GCB group. The c-MYC rearrangement had statistical significance between GCB and non-GCB groups (P＜0.05). Conclusions　The GCB group in patients with DLBCL has a high c-MYC rearrangement，and c-MYC rearrangement is a poor predictor for a part of GCB group. FISH is a rapid，accurate and sensitive technique for the detection of c-MYC rearrangement.

Key words: c-MYC rearrangement, Diffuse large B-cell lymphoma, Fluorescence in situ hybridization

WANG Zhilin 1，YAO Yuhua 2，LI Sang 1，SUN Guanxing 1. Research on correlation between immunophenotype and c-MYC rearrangement in diffuse large B-cell lymphoma[J]. , 2013, 28(4): 308-311.

References

[1]Sabattini E, Bacci F, Sagramoso C, et al. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008:an overview[J].Pathologica,2010, 102(3):83-87.
[2]Alizadeh AA，Eisen MB，Davis RE,et al．Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling[J]．Nature，2000，403(6769)：503-511．
[3]Hans CP，Weisenburger DD，Greiner TC，et al．Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]．Blood，2004，103(1)：275-282．
[4]Au WY,Horsman DE,Gascoyne RD,et al.The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases [J].Leuk Lymphoma,2004,45(3):519-528.
[5]Sehn LH，Berry B，Chhanabhai M，et al. The revised international prognostic index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP[J]. Blood，2007,109(5) :1857-1861.
[6]Yoon SO,Jeon YK,Paik JH,et al. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL),especially in germinal centre-like B cell (GCB) type [J].Histopathology,2008,53(2):205-217.
[7]Savage KJ,Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy[J].Blood,2009,114(17):3533-3537.
[8]Snuderl M,Kolman OK,Chen YB,et al.B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma[J].Am J Surg Pathol,2010,34(3):327-340.
[9]Ninan MJ,Wadhwa PD,Gupta P，et al.Prognostication of diffuse large B-cell lymphoma in the rituximab era [J]. Leuk Lymphoma,2011,52(3):360-373.
[10]He L，He X，Lim LP，et al. A microRNA component of the p53 tumour suppressor network[J]. Nature，2007,447(7148):1130-1134.
[11]Tzankov A，Schneider A，Hoeller S，et al. Prognostic importance of BCL6 rearrangements in diffuse large B-cell lymphoma with respect to Bcl6 protein levels and primary lymphoma site[J]. Hum Pathol，2009,40(7):1055-1056.

Research on correlation between immunophenotype and c-MYC rearrangement in diffuse large B-cell lymphoma

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

[1]	RUAN Ming, LIN Han, WANG Jianbiao, LÜ Lingling, ZHU Wenhua, XU Jiayue, LI Weili, ZHU Weirong. Effect of Qinhuang Formula on immune function of patients with diffuse large B-cell lymphoma after R-CHOP chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 403-408.
[2]	SUN Hengjuan, DU Chengkan, LI Hong, LIU Min, ZHANG Hong. Diagnostic value of cytogenetics in acute leukemia with MLL gene abnormality [J]. Laboratory Medicine, 2022, 37(12): 1196-1199.
[3]	LI Bin, ZHAO Dong, HUANG Rong, GUO Juansun. Role of bone marrow vascular endothelial growth factor levels in patients with diffuse large B-cell lymphoma after treatment [J]. Laboratory Medicine, 2021, 36(5): 480-485.
[4]	YUAN Qinwei, GUO Yongcan, CHEN Chen, YE Runfa. Roles of lymphocyte parameters in the diagnosis of diffuse large B-cell lymphoma [J]. Laboratory Medicine, 2019, 34(12): 1114-1117.